|
|
|
Volumn 13, Issue 70, 2004, Pages 71-76
|
|
Industrial interests versus public health: The gap is growing
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
ADEFOVIR DIPIVOXIL;
BENZOPORPHYRIN DERIVATIVE;
BETA1A INTERFERON;
CAPECITABINE;
CEFOTIAM;
DACLIZUMAB;
DOXORUBICIN;
ESTRADIOL;
ETANERCEPT;
GESTODENE;
HUMAN GROWTH HORMONE;
IMATINIB;
LAMOTRIGINE;
LETROZOLE;
LOPERAMIDE;
MEMANTINE;
OLANZAPINE;
PARACETAMOL;
PAROXETINE;
RECOMBINANT CHORIONIC GONADOTROPIN;
RECOMBINANT FOLLITROPIN;
RITUXIMAB;
ROFECOXIB;
THALIDOMIDE;
TRAMADOL;
UNINDEXED DRUG;
VALACICLOVIR;
VORICONAZOLE;
ZOLEDRONIC ACID;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SURVEILLANCE PROGRAM;
HEALTH CARE COST;
HUMAN;
NOTE;
PHARMACEUTICAL CARE;
PHARMACY;
PRESCRIPTION;
PROFIT;
PUBLIC HEALTH;
RISK BENEFIT ANALYSIS;
SELF MEDICATION;
CONFLICT OF INTEREST;
DRUG INDUSTRY;
DRUG PACKAGING;
DRUGS, GENERIC;
ECONOMIC COMPETITION;
EUROPE;
FRANCE;
HUMANS;
LEGISLATION, DRUG;
MARKETING;
PUBLIC HEALTH;
|
|
EID: 1842865076
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|